Periprocedural myocardial injury during transcatheter aortic valve implantation
S. V. Maingart,
K. A. Lashevich,
M. A. Yusupova,
P. A. Lazebny,
A. N. Fedorchenko,
V. A. Porkhanov,
V. V. Lomivorotov,
A. A. Baranov,
O. V. Krestyaninov https://doi.org/10.15829/1728-8800-2026-4613
EDN: YZDMVX
Abstract
Transcatheter aortic valve implantation (TAVI) is an effective minimally invasive treatment for patients with severe aortic stenosis and varying surgical risks. However, like any surgery, TAVI is associated with various complications, including periprocedural myocardial injury. This issue remains understudied, and numerous questions remain unresolved, including not only the diagnosis of periprocedural myocardial injury after TAVI but also the long-term prognosis for patients who experience this complication. This article highlights the following issues related to periprocedural myocardial injury after TAVI: definition, pathogenesis, diagnosis, and its impact on short-term and long-term treatment outcomes.
About the Authors
S. V. Maingart
Research Institute — Ochapovsky Regional Clinical Hospital № 1; Kuban State Medical University
Russian Federation
Russian Federation
May str., 169, Krasnodar, 350086; Sedina str., 4, Krasnodar, 350063
K. A. Lashevich
Research Institute — Ochapovsky Regional Clinical Hospital № 1
Russian Federation
Russian Federation
May str., 169, Krasnodar, 350086
M. A. Yusupova
Research Institute — Ochapovsky Regional Clinical Hospital № 1
Russian Federation
Russian Federation
May str., 169, Krasnodar, 350086
P. A. Lazebny
Research Institute — Ochapovsky Regional Clinical Hospital № 1
Russian Federation
Russian Federation
May str., 169, Krasnodar, 350086
A. N. Fedorchenko
Research Institute — Ochapovsky Regional Clinical Hospital № 1; Kuban State Medical University
Russian Federation
Russian Federation
May str., 169, Krasnodar, 350086; Sedina str., 4, Krasnodar, 350063
V. A. Porkhanov
Research Institute — Ochapovsky Regional Clinical Hospital № 1; Kuban State Medical University
Russian Federation
Russian Federation
May str., 169, Krasnodar, 350086; Sedina str., 4, Krasnodar, 350063
V. V. Lomivorotov
Meshalkin National Medical Research Center
Russian Federation
Russian Federation
Rechkunovskaya str., 15, Novosibirsk, 630055
A. A. Baranov
Meshalkin National Medical Research Center
Russian Federation
Russian Federation
Rechkunovskaya str., 15, Novosibirsk, 630055
O. V. Krestyaninov
Meshalkin National Medical Research Center; Novosibirsk State Medical University
Russian Federation
Russian Federation
Rechkunovskaya str., 15, Novosibirsk, 630055; Krasny Prospekt, 52, Novosibirsk, 630091
References
1. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis. Circulation. 2002;106(24):3006-8. doi:10.1161/01.cir.0000047200.36165.b8.
2. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. EuroIntervention. 2022;17(14):e1126-96. doi:10.4244/eij-e-21-00009.
3. Filomena D, Monosilio S, Cimino S, et al. Prognostic role of preand postinterventional myocardial injury in patients undergoing transcatheter aortic valve implantation. Minerva Cardiol Angiol. 2023;71(1):77-82. doi:10.23736/s2724-5683.21.05630-1.
4. Köhler WM, Freitag-Wolf S, Lambers M, et al. Preprocedural but not periprocedural high-sensitive Troponin T levels predict outcome in patients undergoing transcatheter aortic valve implantation. Cardiovasc Ther. 2016;34(6):385-96. doi:10.1111/1755-5922.12208.
5. Koskinas KC, Stortecky S, Franzone A, et al. Post-Procedural Troponin Elevation and Clinical Outcomes Following Transcatheter Aortic Valve Implantation. J Am Heart Assoc. 2016;5(2):e002430. doi:10.1161/jaha.115.002430.
6. Sinning JM, Hammerstingl C, Schueler R, et al. The prognostic value of acute and chronic troponin elevation after transcatheter aortic valve implantation. EuroIntervention. 2016;11(13):1522-9. doi:10.4244/eijy15m02_02.
7. Barbash IM, Dvir D, Ben-Dor I, et al. Prevalence and effect of myocardial injury after transcatheter aortic valve replacement. Am J Cardiol. 2013;111(9):1337-43. doi:10.1016/j.amjcard.2012.12.059.
8. Yong ZY, Wiegerinck EMA, Boerlage-van Dijk K, et al. Predictors and prognostic value of myocardial injury during transcatheter aortic valve implantation. Circ Cardiovasc Interv. 2012;5(3):415-23. doi:10.1161/circinterventions.111.964882.
9. Stundl A, Schulte R, Lucht H, et al. Periprocedural Myocardial Injury Depends on Transcatheter Heart Valve Type But Does Not Predict Mortality in Patients After Transcatheter Aortic Valve Replacement. JACC: Cardiovasc Interv. 2017;10(15):1550-60. doi:10.1016/j.jcin.2017.05.029.
10. Nara Y, Watanabe Y, Kataoka A, et al. Incidence, predictors, and midterm clinical outcomes of myocardial injury after transcatheter aortic-valve implantation. Int Heart J. 2018;59(6):1296-302. doi:10.1536/ihj.17-645.
11. Dagan M, Dawson LP, Stehli J, et al. Periprocedural Myocardial Injury and Coronary Artery Disease in Patients Undergoing Transcatheter Aortic Valve Replacement. Cardiovasc Revasc Med. 2022;35:8-15. doi:10.1016/j.carrev.2021.04.006.
12. Sharma V, Dey T, Sankaramangalam K, et al. Prognostically Significant Myocardial Injury in Patients Undergoing Transcatheter Aortic Valve Replacement. J Am Heart Assoc. 2019;8(14). doi:10.1161/jaha.118.011889.
13. Mirna M, Wernly B, Eder S, et al. Transcatheter aortic valve implantation without prior balloon valvuloplasty is associated with less pronounced markers of myocardial injury. J Cardiovasc Surg. 2020;61(2):243-9. doi:10.23736/s0021-9509.18.10651-3.
14. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg. 2012;42(5):45-60. doi:10.1093/ejcts/ezs533.
15. Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J. 2011;32(2):205-17. doi:10.1093/eurheartj/ehq406.
16. Généreux P, Piazza N, Alu MC, et al. Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research. J Am Coll Cardiol. 2021;77(21):2717-46. doi:10.1016/j.jacc.2021.02.038.
17. Oury C, Nchimi A, Lancellotti P, et al. Can Blood Biomarkers Help Predicting Outcome in Transcatheter Aortic Valve Implantation? Front Cardiovasc Med. 2018;28(5):31. doi:10.3389/fcvm.2018.00031.
18. Real C, Avvedimento M, Nuche J, et al. Myocardial Injury After Transcatheter Aortic Valve Replacement According to VARC-3 Criteria. JACC: Cardiovasc Interv. 2023;16(10):1221-32. doi:10.1016/j.jcin.2023.03.022.
19. De Marzo V, Crimi G, Vercellino M, et al. Impact of bioprosthetic valve type on peri-procedural myocardial injury and mortality after transcatheter aortic valve replacement. Heart Vessels. 2021;36(11):1746-55. doi:10.1007/s00380-021-01861-8.
20. Baranov AA, Badoyan AG, Khelimskiy DA, et al. Predictors and impact of myocardial injury (VARC-3 criteria) after transcatheter aortic valve implantation. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;17(5):489-98. (In Russ.) doi:10.17116/kardio202417051489.
21. Stolte T, Lopez-Ayala P, Reichl J, et al. The impact of myocardial injury on outcomes in TAVI patients. Clin Res Cardiol. 2025; 114(3):385-94. doi: 10.1007/s00392-024-02585-1.
22. Thygesen K, Alpert JS, Jaffe AS, et al; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction; Katus HA, Lindahl B, Morrow DA et al. Third universal definition of myocardial infarction. Circulation. 2012;126(16):2020-35. doi:10.1161/cir.0b013e31826e1058.
23. Guney MC, Keles T, Karaduman BD, et al. Predictors and Prognostic Implications of Myocardial Injury After Transcatheter Aortic Valve Replacement. Tex Heart Inst J. 2022;49(4). doi:10.14503/thij-20-7380.
24. Akodad M, Roubille F, Marin G, et al. Myocardial Injury After Balloon Predilatation Versus Direct Transcatheter Aortic Valve Replacement: Insights From the DIRECTAVI Trial. J Am Heart Assoc. 2020;9(24). doi:10.1161/jaha.120.018405.
25. Greco A, Spagnolo M, Capodanno D. Antithrombotic therapy after transcatheter aortic valve implantation. Expert Rev Med Devices. 2022;19(6):499-513. doi:10.1080/17434440.2022.2106853.
26. Leclercq F, Robert P, Akodad M, et al. Prior Balloon Valvuloplasty Versus Direct Transcatheter Aortic Valve Replacement: Results From the DIRECTAVI Trial. JACC: Cardiovasc Interv. 2020;13(5):594-602. doi:10.1016/j.jcin.2019.12.006.
27. Schindler M, Stöckli F, Brütsch R, et al. Postprocedural troponin elevation and mortality after transcatheter aortic valve implantation. J Am Heart Assoc. 2021;10(21):e020739. doi:10.1161/jaha.120.020739.
28. Akodad M, Spaziano M, Chevalier B, et al. Prognostic Impact of Pre-Transcatheter and Post-Transcatheter Aortic Valve Intervention Troponin: A Large Cohort Study. J Am Heart Assoc. 2019;8(6). doi:10.1161/jaha.118.011111.
29. Ribeiro HB, Nombela-Franco L, Muñoz-García AJ, et al. Predictors and Impact of Myocardial Injury After Transcatheter Aortic Valve Replacement A Multicenter Registry. J Am Coll Cardiol. 2015;66(19):2075-88. doi:10.1016/j.jacc.2015.08.881.
30. Rahhab Z, Labarre Q, Nijenhuis VJ, et al. Myocardial Injury Post Transcatheter Aortic Valve Implantation Comparing Mechanically Expanded Versus Self-Expandable Versus Balloon-Expandable Valves. Structural Heart. 2019;3(5):431-7. doi:10.1080/24748706.2019.1639234.
31. Ribeiro HB, Dahou A, Urena M, et al. Myocardial injury after transaortic versus transapical transcatheter aortic valve replacement. Ann Thorac Surg. 2015;99(6):2001-9. doi:10.1016/j.athoracsur.2015. 01.029.
32. Ribeiro HB, Larose É, De La Paz Ricapito M, et al. Myocardial injury following transcatheter aortic valve implantation: Insights from delayed-enhancement cardiovascular magnetic resonance. EuroIntervention. 2015;11(2):205-13. doi:10.4244/eijv11i2a39.
33. Ben-Dor I, Pichard AD, Satler LF, et al. Complications and outcome of balloon aortic valvuloplasty in high-risk or inoperable patients. JACC: Cardiovasc Interv. 2010;3(11):1150-6. doi:10.1016/j.jcin.2010.08.014.
34. Haberthür D, Lutter G, Appel M, et al. Percutaneous aortic valve replacement: valvuloplasty studies in vitro. Eur J Cardiothorac Surg. 2011;39(5):631-4. doi:10.1016/j.ejcts.2010.07.045.
35. Kahlert P, Al-Rashid F, Plicht B, et al. Myocardial injury during transfemoral transcatheter aortic valve implantation: an intracoronary Doppler and cardiac magnetic resonance imaging study. EuroIntervention. 2016;11(12):1401-8. doi:10.4244/eijy15m05_10.
36. Fairbairn TA, Steadman CD, Mather AN, et al. Assessment of valve haemodynamics, reverse ventricular remodelling and myocardial fibrosis following transcatheter aortic valve implantation compared to surgical aortic valve replacement: a cardiovascular magnetic resonance study. Heart. 2013;99(16):1185-91. doi:10.1136/heartjnl2013-303927.
37. Auffret V, Regueiro A, Campelo-Parada F, et al. Feasibility, safety, and efficacy of transcatheter aortic valve replacement without balloon predilation: a systematic review and meta-analysis. Catheter Cardiovasc Interv. 2017;90:839-50. doi:10.1002/ccd.27040.
38. Paradis JM, Maniar HS, Lasala JM, et al. Clinical and Functional Outcomes Associated With Myocardial Injury After Transfemoral and Transapical Transcatheter Aortic Valve Replacement: A Subanalysis From the PARTNER Trial (Placement of Aortic Transcatheter Valves). JACC: Cardiovasc Interv. 2015;8(11):1468-79. doi:10.1016/j.jcin.2015.06.018.
39. Sammour Y, Banerjee K, Kumar A, et al. Systematic Approach to High Implantation of SAPIEN-3 Valve Achieves a Lower Rate of Conduction Abnormalities Including Pacemaker Implantation. Circ Cardiovasc Interv. 2021;14(1):e009407. doi:10.1161/circinterventions.120.009407.
40. Liu Q, Jia K, Yao Y, et al. Peri-procedural myocardial injury predicts poor short-term prognosis after TAVR: A single-center retrospective analysis from China. Chin Med J (Engl). 2023;136(24):3013-5. doi:10.1097/cm9.0000000000002843.
41. Thygesen K, Mair J, Giannitsis E, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J. 2012; 33(18): 2252-7. doi:10.1093/eurheartj/ehs154.
42. White M, Baral R, Ryding A, et al. Biomarkers Associated with Mortality in Aortic Stenosis: A Systematic Review and Meta-Analysis. Med Sci (Basel). 2021;9(2):29. doi:10.3390/medsci9020029.
43. Takagi H, Hari Y, Nakashima K, et al; All-Literature Investigation of Cardiovascular Evidence (ALICE) Group. Meta-analysis of impact of troponins on mortality after transcatheter aortic valve implantation. J Cardiovasc Surg (Torino). 2020;61(1):98-106. doi:10.23736/s0021-9509.19.11023-3.
44. Seoudy H, Lambers M, Winkler V, et al. Elevated high-sensitivity troponin T levels at 1-year follow-up are associated with increased long-term mortality after TAVR. Clin Res Cardiol. 2021;110(3):421-8. doi:10.1007/s00392-020-01759-x.
45. Koifman E, Garcia-Garcia HM, Alraies MC, et al. Correlates and Significance of Elevation of Cardiac Biomarkers Elevation Following Transcatheter Aortic Valve Implantation. Am J Cardiol. 2017;120(5):850-6. doi:10.1016/j.amjcard.2017.05.059.
46. Michail M, Cameron JN, Nerlekar N, et al. Periprocedural myocardial injury predicts shortand long-term mortality in patients undergoing transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2018;11(11):e007106. doi:10.1161/circinterventions.118.007106.
47. de Sá Marchi MF, Calomeni P, Gauza M de M, et al. Impact of periprocedural myocardial injury after transcatheter aortic valve implantation on long-term mortality: a meta-analysis of KaplanMeier derived individual patient data. Front Cardiovasc Med. 2023;10:1228305. doi:10.3389/fcvm.2023.1228305.
48. Chen W, Han Y, Wang C, et al. Association between periprocedural myocardial injury and long-term all-cause mortality in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis. Scand Cardiovasc J. 2022;56(1):387-93. doi:10.1080/14017431.2022.2139412.
What is already known about the subject?
- Periprocedural myocardial injury (PMI) is one of the most common complications after transcatheter aortic valve implantation (TAVI).
- PMI diagnostic criteria, based on the dynamics of myocardial injury biomarkers, are constantly being revised and refined.
- The short- and long-term prognosis of patients with PMI remains unclear.
- Effective strategies for PMI prevention have not yet been developed.
What might this study add?
- The introduction of novel, improved PMI diagnostic criteria (VARC-3) has led to more stringent verification of the complication. However, the incidence of PMI in TAVI remains clinically significant.
- The diagnostic and prognostic value of key myocardial injury biomarkers (troponin and creatine phosphokinase MB) requires clarification.
- Despite the introduction of VARC-3 criteria to improve risk stratification in a cohort of patients with myocardial infarction who underwent TAVI, short- and long-term prognosis data remain characterized by significant heterogeneity.
Review
For citations:
Maingart S.V., Lashevich K.A., Yusupova M.A., Lazebny P.A., Fedorchenko A.N., Porkhanov V.A., Lomivorotov V.V., Baranov A.A., Krestyaninov O.V. Periprocedural myocardial injury during transcatheter aortic valve implantation. Cardiovascular Therapy and Prevention. 2026;25(4):4613. (In Russ.) https://doi.org/10.15829/1728-8800-2026-4613. EDN: YZDMVX
Views:
175
JATS XML
Email this article 
